Locations:

Tag: semaglutide

June 10, 2024/Diabetes & Endocrinology/Research

De-Intensification From Basal Bolus to Subcutaneous Semaglutide and Basal Insulin

TRANSITION-T2D RCT results for patients with T2D receiving MDI

Photo of patient injecting drug into stomach

February 22, 2024/Primary Care/Research

Cleveland Clinic Study Identifies Factors Associated With Long-Term Use of Popular Anti-Obesity Medications

Perserverance may depend on several specifics, including medication type, insurance coverage and medium-term weight loss

illustration showing action of a GLP-1 receptor agonist

November 20, 2023/Heart, Vascular and Thoracic/Preventive Cardiology

Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes

Findings establish overweight/obesity as a modifiable risk factor for cardiovascular disease

22-HVI-3411464_GLP-1-and-GIP-dual-agonism_650x450

December 19, 2022/Heart, Vascular and Thoracic/Preventive Cardiology

New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight

Two major trials promise key progress against the last unaddressed major risk factor

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

BackPage 1 of 1Next